Zealand Pharma A/S (OTCMKTS:ZLDPF) Sees Unusually-High Trading Volume – Still a Buy?

Shares of Zealand Pharma A/S (OTCMKTS:ZLDPF) saw unusually-strong trading volume on Monday . Approximately 1,480 shares changed hands during mid-day trading, an increase of 9% from the previous session’s volume of 1,360 shares.The stock last traded at $63.19 and had previously closed at $66.84.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on ZLDPF shares. Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of Zealand Pharma A/S in a report on Tuesday, December 16th. Zacks Research upgraded Zealand Pharma A/S from a “strong sell” rating to a “hold” rating in a research note on Monday, September 15th. Finally, BTIG Research upgraded Zealand Pharma A/S to a “strong-buy” rating in a research report on Friday, November 28th. Six equities research analysts have rated the stock with a Strong Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, Zealand Pharma A/S has a consensus rating of “Strong Buy”.

Zealand Pharma A/S Stock Down 3.5%

The firm’s 50-day moving average price is $76.20 and its 200 day moving average price is $68.95. The company has a current ratio of 14.10, a quick ratio of 14.10 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $4.51 billion, a price-to-earnings ratio of 4.57 and a beta of 0.74.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($0.90) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.11) by $0.21. Zealand Pharma A/S had a net margin of 71.79% and a return on equity of 55.76%. The business had revenue of $7.76 million for the quarter, compared to analysts’ expectations of $4.54 million. On average, sell-side analysts forecast that Zealand Pharma A/S will post -2.19 EPS for the current fiscal year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.